Àngels García-Cazorla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Àngels García-Cazorla has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Rafael Artuch
Clinical Biochemistry Department, Hospital Sant Joan de Déu, Barcelona, Spain; Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain; Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Barcelona, Spain
27 shared publications Aida Ormazábal
9 shared publications- Mercedes Serrano
Neuropediatric Department, Hospital Sant Joan de Déu Institut de Recerca Sant Joan de Déu (IRSJD) Barcelona Spain
9 shared publications Rafael Artuch
Clinical Biochemistry Department, Hospital Sant Joan de Deu, IRSJD, Barcelona, Spain. Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain
9 shared publications- Judith Armstrong
Laboratory Service‐ Genomics Unit Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Deu, CIBERER Barcelona Spain
8 shared publications - Alba Tristán-Noguero
Neurometabolic Unit and Synaptic Metabolism Lab, Neurology Department, Institut Pediàtric de Recerca and MetabERN Hospital Sant Joan de Déu Barcelona Spain
7 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley in Advanced Intelligent Systems
AI‐Based Mitochondrial Network Characterization as a Biomarker for DNM1L ‐Related Disease Diagnosis
Pathogenic variants in DNM1L impair Drp1 function, a key regulator of mitochondrial and peroxisomal fission, leading to a neurodevelopmental disorder with a broad clinical spectrum. The clinical and functional heterogeneity of Drp1 deficiency complicates the interpretation of new variants of unknown significance, hindering the disease diagnosis and proper management. This proof‐of‐concept study evaluates whether AI‐based mitochondrial network phenotyping could serve as a characteristic feature of DNM1L mutations, supporting the disease diagnosis. Using fluorescent confocal microscopy images, supervised machine‐learning classification of the mitochondrial network features of DNM1L ‐ patients’ primary fibroblasts enables discrimination from controls and other mitochondrial disorders. To avoid manual data extraction, the deep‐learning Convolutional Neural Network (CNN) EfficientNetB0 is used, following two approaches: direct Fine‐Tuning (FT) and Curriculum‐learning Fine‐Tuning (CFT), in which the model is trained from easy‐to‐complex microscopy images to extract hierarchical visual features. Among these, CFT achieves the best performance, with 77% accuracy and 0.92 AUC (Area Under the ROC Curve), thereby optimally discerning DNM1L mitochondrial networks from other mitochondrial disorders. Overall, these findings provide proof‐of‐concept that mitochondrial network morphology in patient‐derived fibroblasts may constitute a disease‐associated phenotypic signature of DNM1L deficiency and a potentially useful complementary functional readout for the interpretation of DNM1L variants. Further validation in larger cohorts and across independent experimental settings will be required before considering its clinical diagnostic application.
- 5 November 2026
- Published by Wiley in Advanced Intelligent Systems
Open AccessAI‐Based Mitochondrial Network Characterization as a Biomarker for DNM1L ‐Related Disease Diagnosis
Pathogenic variants in DNM1L impair Drp1 function, a key regulator of mitochondrial and peroxisomal fission, leading to a neurodevelopmental disorder with a broad clinical spectrum. The clinical and functional heterogeneity of Drp1 deficiency complicates the interpretation of new variants of unknown significance, hindering the disease diagnosis and proper management. This proof‐of‐concept study evaluates whether AI‐based mitochondrial network phenotyping could serve as a characteristic feature of DNM1L mutations, supporting the disease diagnosis. Using fluorescent confocal microscopy images, supervised machine‐learning classification of the mitochondrial network features of DNM1L ‐ patients’ primary fibroblasts enables discrimination from controls and other mitochondrial disorders. To avoid manual data extraction, the deep‐learning Convolutional Neural Network (CNN) EfficientNetB0 is used, following two approaches: direct Fine‐Tuning (FT) and Curriculum‐learning Fine‐Tuning (CFT), in which the model is trained from easy‐to‐complex microscopy images to extract hierarchical visual features. Among these, CFT achieves the best performance, with 77% accuracy and 0.92 AUC (Area Under the ROC Curve), thereby optimally discerning DNM1L mitochondrial networks from other mitochondrial disorders. Overall, these findings provide proof‐of‐concept that mitochondrial network morphology in patient‐derived fibroblasts may constitute a disease‐associated phenotypic signature of DNM1L deficiency and a potentially useful complementary functional readout for the interpretation of DNM1L variants. Further validation in larger cohorts and across independent experimental settings will be required before considering its clinical diagnostic application.
- 2 October 2026
- Published by Cambridge University Press (CUP) in Behavioral and Brain Sciences
- Vol. 49, e461
Beyond energy: Expanding metabolic considerations in cognitive modeling
Integrating metabolism into cognitive science is essential. Beyond a mere constraint, metabolism may be constitutive of cognition itself. This requires expanding metabolism beyond neuronal energy use to include glial contributions, compartmentalized and dynamic processes, and broader brain–body interactions (e.g., interoception). Capturing this complexity will require more refined, integrative models, potentially leveraging artificial intelligence to unify multiscale biological data.
- 2 October 2026
- Published by Cambridge University Press (CUP) in Behavioral and Brain Sciences
- Vol. 49, e461
Beyond energy: Expanding metabolic considerations in cognitive modeling
Integrating metabolism into cognitive science is essential. Beyond a mere constraint, metabolism may be constitutive of cognition itself. This requires expanding metabolism beyond neuronal energy use to include glial contributions, compartmentalized and dynamic processes, and broader brain–body interactions (e.g., interoception). Capturing this complexity will require more refined, integrative models, potentially leveraging artificial intelligence to unify multiscale biological data.
- 27 August 2026
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (5) , e70242
Treating a Disorder Caused by an Overactive Enzyme: BCKD‐Kinase Deficiency
Branched‐chain ketoacid dehydrogenase kinase (BCKDK) deficiency is a rare autosomal recessive disorder. Loss of this kinase leaves the branched‐chain α‐ketoacid dehydrogenase complex constitutively active, leading to depletion of branched‐chain amino acids (BCAAs) rather than their accumulation. To date, 31 patients from 20 families have been reported. In the largest systematic series, global developmental delay and intellectual disability are universal, autism spectrum disorder occurs in 71%, epilepsy in 43%, and progressive postnatal microcephaly. Mean age at diagnosis is close to 6 years, partly because the clinical picture resembles many forms of idiopathic neurodevelopmental disability. Treatment with a high‐protein diet (≥ 2 g/kg/day) and BCAA supplementation (100–250 mg/kg/day) can normalize plasma BCAA levels and appears to stabilize motor function and head circumference. In the limited data available, three patients who started treatment before age 2 did not develop autism, and the earliest‐treated patient (8 months) was developing normally at 3 years of follow‐up. However, current therapy has clear limitations. Tracer studies in Bckdk knockout mice show reduced incorporation of BCAA‐derived nitrogen into brain glutamate even with dietary intervention, pointing to a gap between peripheral biochemical correction and what the brain actually receives. Emerging strategies include partial pharmacological suppression of BCKDH activity, stabilization of residual mutant BCKDK protein, and gene therapy. Newborn screening, feasible with existing technology, deserves consideration given the contrast in outcomes between early and late treatment. This review examines what current treatment achieves, where it falls short, and what additional strategies may be needed.
- 27 August 2026
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (5) , e70242
Treating a Disorder Caused by an Overactive Enzyme: BCKD‐Kinase Deficiency
Branched‐chain ketoacid dehydrogenase kinase (BCKDK) deficiency is a rare autosomal recessive disorder. Loss of this kinase leaves the branched‐chain α‐ketoacid dehydrogenase complex constitutively active, leading to depletion of branched‐chain amino acids (BCAAs) rather than their accumulation. To date, 31 patients from 20 families have been reported. In the largest systematic series, global developmental delay and intellectual disability are universal, autism spectrum disorder occurs in 71%, epilepsy in 43%, and progressive postnatal microcephaly. Mean age at diagnosis is close to 6 years, partly because the clinical picture resembles many forms of idiopathic neurodevelopmental disability. Treatment with a high‐protein diet (≥ 2 g/kg/day) and BCAA supplementation (100–250 mg/kg/day) can normalize plasma BCAA levels and appears to stabilize motor function and head circumference. In the limited data available, three patients who started treatment before age 2 did not develop autism, and the earliest‐treated patient (8 months) was developing normally at 3 years of follow‐up. However, current therapy has clear limitations. Tracer studies in Bckdk knockout mice show reduced incorporation of BCAA‐derived nitrogen into brain glutamate even with dietary intervention, pointing to a gap between peripheral biochemical correction and what the brain actually receives. Emerging strategies include partial pharmacological suppression of BCKDH activity, stabilization of residual mutant BCKDK protein, and gene therapy. Newborn screening, feasible with existing technology, deserves consideration given the contrast in outcomes between early and late treatment. This review examines what current treatment achieves, where it falls short, and what additional strategies may be needed.
- Open Access
- 20 July 2026
- Published by Elsevier in NeuroImage: Clinical
- Vol. 51, 104038
Brain structure abnormalities in neurodevelopmental synaptopathies
- 20 July 2026
- Published by Elsevier in NeuroImage: Clinical
- Vol. 51, 104038
Open AccessBrain structure abnormalities in neurodevelopmental synaptopathies
- Open Access
- 18 June 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (2) , 44
Health Outcomes of Patients with Distal Urea Cycle Disorders Detected by Newborn Screening: Data from the Spanish National Registry
Urea cycle disorders (UCDs) are rare inherited metabolic diseases associated with toxic hyperammonemia, leading to severe neurological damage and early mortality. Early diagnosis of distal UCDs through newborn screening (NBS) enables presymptomatic intervention; however, comparative real-world outcome data remain limited. We conducted a retrospective, multicenter study using data from the Spanish UCD Registry to describe the clinical characteristics and compare health outcomes between patients diagnosed through NBS (n = 40) and those diagnosed after clinical presentation (n = 53). Patients identified by NBS showed a markedly more favorable clinical prognosis, with a mortality rate of 2.5% compared with 15.1% in the unscreened cohort, as well as significantly lower rates of neurological involvement, fewer hospital admissions due to metabolic decompensation, and a reduced need for liver transplantation. Screening also identified a high prevalence of argininosuccinate synthetase deficiency (ASS1D) cases with attenuated biochemical profiles, highlighting the relevance of sensitive screening cutoffs. These findings provide real-world evidence that presymptomatic diagnosis through NBS is associated with improved survival and long-term neurological outcomes in patients with distal UCDs.
- 18 June 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (2) , 44
Open AccessHealth Outcomes of Patients with Distal Urea Cycle Disorders Detected by Newborn Screening: Data from the Spanish National Registry
Urea cycle disorders (UCDs) are rare inherited metabolic diseases associated with toxic hyperammonemia, leading to severe neurological damage and early mortality. Early diagnosis of distal UCDs through newborn screening (NBS) enables presymptomatic intervention; however, comparative real-world outcome data remain limited. We conducted a retrospective, multicenter study using data from the Spanish UCD Registry to describe the clinical characteristics and compare health outcomes between patients diagnosed through NBS (n = 40) and those diagnosed after clinical presentation (n = 53). Patients identified by NBS showed a markedly more favorable clinical prognosis, with a mortality rate of 2.5% compared with 15.1% in the unscreened cohort, as well as significantly lower rates of neurological involvement, fewer hospital admissions due to metabolic decompensation, and a reduced need for liver transplantation. Screening also identified a high prevalence of argininosuccinate synthetase deficiency (ASS1D) cases with attenuated biochemical profiles, highlighting the relevance of sensitive screening cutoffs. These findings provide real-world evidence that presymptomatic diagnosis through NBS is associated with improved survival and long-term neurological outcomes in patients with distal UCDs.
- Open Access
- 10 March 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (5) , e214657
Use of Brain MRI in Cerebral Adrenoleukodystrophy
Background and ObjectivesCerebral adrenoleukodystrophy (CALD) is a common manifestation of adrenoleukodystrophy (ALD) in men. Early detection of CALD lesions through MRI screening is critical to al...
- 10 March 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (5) , e214657
Open AccessUse of Brain MRI in Cerebral Adrenoleukodystrophy
Background and ObjectivesCerebral adrenoleukodystrophy (CALD) is a common manifestation of adrenoleukodystrophy (ALD) in men. Early detection of CALD lesions through MRI screening is critical to al...
- Open Access
- 17 February 2026
- Published by Springer Nature in Pediatric Research
Cross-border access to clinical trials: participation of pediatric patients and language inclusion
Cross-border access to clinical trials in Europe lacks specific regulation. Language diversity in Europe, with 24 official languages, is a key factor that must be considered when including international pediatric patients in multi-country studies. Providing translation enables patients to participate in clinical trials across borders. Specific consideration requires pediatric rare disease clinical trials for conditions with no approved treatment, where only a few countries participate, making cross-border access even more critical. We analyzed retrospective data (2011-2024) of the studies incorporating international patients at SJD Barcelona Children's Hospital. The main objective of this research was to assess the feasibility of cross-border access to pediatric clinical trials and identify lessons learnt that could help prevent the future exclusion of patients due to their limited proficiency in the official language of the country where the trial site is located. Twenty-one clinical studies have been analyzed. One hundred eighty-one patients from both European and non-European countries (N = 44) were screened, 37.02% of the patients were from Europe, versus 62.98% from non-European countries. In 52.38% of the studies, the translation services were provided by the site; in 14.28% by the sponsor. In 33.33% of the studies, no translation was necessary because the site staff could communicate with the families in Spanish or English. 57.14% of the studies included one or more PROMs or QoL scales, requiring, in some cases, the use of validated translations in the mother tongue of the patient. Participation in pediatric cross-border clinical trials is feasible. The decision to include international patients should prioritize potential medical benefits rather than using the patient's mother tongue or home country as eligibility criteria. Language barriers can be addressed by providing the necessary resources to ensure the scientific reliability of data collected, as well as to enhance the patient experience during participation in a trial abroad. The SJD Barcelona Children's Hospital Clinical Trials Unit operates under a one-stop-shop model, managing clinical studies with a special focus on rare diseases, centralizing all the needs of international patients (translations, accommodation, visas, etc.). The inclusion of international patients in pediatric clinical studies is feasible. Pediatric rare diseases require a small sample of patients, highly specialized sites, and flexibility to accommodate the necessary translations for patients. The final decision regarding the inclusion of international patients lies with the sponsor. Flexibility in including international patients directly impacts the study plan and execution, preventing time deviations.
- 17 February 2026
- Published by Springer Nature in Pediatric Research
Open AccessCross-border access to clinical trials: participation of pediatric patients and language inclusion
Cross-border access to clinical trials in Europe lacks specific regulation. Language diversity in Europe, with 24 official languages, is a key factor that must be considered when including international pediatric patients in multi-country studies. Providing translation enables patients to participate in clinical trials across borders. Specific consideration requires pediatric rare disease clinical trials for conditions with no approved treatment, where only a few countries participate, making cross-border access even more critical. We analyzed retrospective data (2011-2024) of the studies incorporating international patients at SJD Barcelona Children's Hospital. The main objective of this research was to assess the feasibility of cross-border access to pediatric clinical trials and identify lessons learnt that could help prevent the future exclusion of patients due to their limited proficiency in the official language of the country where the trial site is located. Twenty-one clinical studies have been analyzed. One hundred eighty-one patients from both European and non-European countries (N = 44) were screened, 37.02% of the patients were from Europe, versus 62.98% from non-European countries. In 52.38% of the studies, the translation services were provided by the site; in 14.28% by the sponsor. In 33.33% of the studies, no translation was necessary because the site staff could communicate with the families in Spanish or English. 57.14% of the studies included one or more PROMs or QoL scales, requiring, in some cases, the use of validated translations in the mother tongue of the patient. Participation in pediatric cross-border clinical trials is feasible. The decision to include international patients should prioritize potential medical benefits rather than using the patient's mother tongue or home country as eligibility criteria. Language barriers can be addressed by providing the necessary resources to ensure the scientific reliability of data collected, as well as to enhance the patient experience during participation in a trial abroad. The SJD Barcelona Children's Hospital Clinical Trials Unit operates under a one-stop-shop model, managing clinical studies with a special focus on rare diseases, centralizing all the needs of international patients (translations, accommodation, visas, etc.). The inclusion of international patients in pediatric clinical studies is feasible. Pediatric rare diseases require a small sample of patients, highly specialized sites, and flexibility to accommodate the necessary translations for patients. The final decision regarding the inclusion of international patients lies with the sponsor. Flexibility in including international patients directly impacts the study plan and execution, preventing time deviations.
- Open Access
Synaptic networks shape clinical phenotypes in neurodevelopmental disorders: An integrative clinical, genetic and biological perspective
Background: Clinical variability in synaptopathies suggests complex multidimensional interactions. The resulting phenotypes depend not only on the affected gene, but also on its functional role, subcellular localization, and spatiotemporal brain expression, among other potential influencing factors. Here, we present a proof of concept integrating genetic, synaptic, and developmental expression data to explore how shared pathways can lead to similar clinical manifestations across different synaptic disorders.We systematically curated published clinical data from 1,648 patients with pathogenic variants in 20 synaptic genes, through deep phenotyping using standardized Human Phenotype Ontology (HPO) annotation. Functional gene groups were defined based on synaptic localization, biological process, brain expression patterns and disease onset. Brain developmental expression data were obtained from the BrainSpan Atlas, normalized, and analyzed to assess gene co-expression and timing of peak expression. Results: Integrating synaptic biology with developmental gene expression data reveals phenotypic emergence through interconnected synaptic characteristics. Subcellular localization shapes manifestations: presynaptic variants associate with motor disorders and postsynaptic variants with broader systemic involvement. Biological processes further refine phenotypes, with transport processes associated with hypotonia and signaling pathways linked to early-onset symptoms. Developmental timing adds dimension: prenatal expression peaks align with cognitive impairments and postpubertal peaks with motor decline. Crucially, clinical profiles mirror co-expression patterns of affected genes, demonstrating dynamic interactions across spatial, functional, and temporal dimensions. Conclusions: By mapping symptoms into synaptic networks across developmental windows, this work establishes the foundation for a “SynGO-Clinic” platform, a clinical extension of SynGO, to advance biological insight, diagnostics, and targeted therapies in neurodevelopmental synaptopathies.
Open AccessSynaptic networks shape clinical phenotypes in neurodevelopmental disorders: An integrative clinical, genetic and biological perspective
Background: Clinical variability in synaptopathies suggests complex multidimensional interactions. The resulting phenotypes depend not only on the affected gene, but also on its functional role, subcellular localization, and spatiotemporal brain expression, among other potential influencing factors. Here, we present a proof of concept integrating genetic, synaptic, and developmental expression data to explore how shared pathways can lead to similar clinical manifestations across different synaptic disorders.We systematically curated published clinical data from 1,648 patients with pathogenic variants in 20 synaptic genes, through deep phenotyping using standardized Human Phenotype Ontology (HPO) annotation. Functional gene groups were defined based on synaptic localization, biological process, brain expression patterns and disease onset. Brain developmental expression data were obtained from the BrainSpan Atlas, normalized, and analyzed to assess gene co-expression and timing of peak expression. Results: Integrating synaptic biology with developmental gene expression data reveals phenotypic emergence through interconnected synaptic characteristics. Subcellular localization shapes manifestations: presynaptic variants associate with motor disorders and postsynaptic variants with broader systemic involvement. Biological processes further refine phenotypes, with transport processes associated with hypotonia and signaling pathways linked to early-onset symptoms. Developmental timing adds dimension: prenatal expression peaks align with cognitive impairments and postpubertal peaks with motor decline. Crucially, clinical profiles mirror co-expression patterns of affected genes, demonstrating dynamic interactions across spatial, functional, and temporal dimensions. Conclusions: By mapping symptoms into synaptic networks across developmental windows, this work establishes the foundation for a “SynGO-Clinic” platform, a clinical extension of SynGO, to advance biological insight, diagnostics, and targeted therapies in neurodevelopmental synaptopathies.
- Open Access
- 22 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 81
Modelling the Transference of Paediatric Patients with Inborn Errors of Metabolism to Adult Hospitals: Clinical Experience
Background/Objectives: Inborn errors of metabolism (IEM) are chronic, life-threatening genetic disorders with a significant cumulative prevalence worldwide. Advances in early diagnosis and treatment have significantly increased life expectancy, underscoring the need for specialised adult care units and the establishment of structured transition programmes from paediatric to adult services. We hereby present a functional transition model for IEM patients and share our implementation experience. Methods: Initiated in 2012, the partnership between the paediatric Hospital Sant Joan de Déu (HSJD) and the adult-care centre at Hospital Clinic of Barcelona (HCB) culminated in 2019 with the transference of the first IEM patients under the structured A10! Programme. This model is structured around the transition units of paediatric and adult centres to guarantee communication and functional management. Regular monthly meetings at each centre and joint quarterly sessions allowed for protocol harmonisation and personalised care planning. Coordinated engagement of the multidisciplinary health care teams with patients and families smoothed the transfer process. Results: Between 2019 and 2024, 94 IEM patients were successfully transferred. Diagnoses included intermediary metabolism defects (71.23%), lipid metabolism and transport disorders (4.25%), heterocyclic compound metabolism (2.12%), complex molecules and organelle dysfunction (6.37%), cofactor and mineral metabolism (2.12%), signalling defects (5.31%), and unclassified cases (8.51% of rare disorders, maybe non-IEM). Transition formats included 21 in-person joint visits in HSJD, 37 remote transitions during the COVID-19 pandemic, and 36 streamlined transfers via standardised protocols. Sessions, trainings, and meetings allowed the exchange of patients’ needs and protocols. Conclusions: The successful transference of IEM patients requires structured programmes with interdisciplinary paediatric and adult teams, joining efforts with the patient, families, and caregivers. Communication between paediatric and adult transition units is essential to promote continuity of care and patient empowerment. While constantly updated, this model has proven effective, gaining positive evaluations from healthcare professionals and patients alike, representing a scalable framework for lifelong management of IEM in adult care settings.
- 22 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 81
Open AccessModelling the Transference of Paediatric Patients with Inborn Errors of Metabolism to Adult Hospitals: Clinical Experience
Background/Objectives: Inborn errors of metabolism (IEM) are chronic, life-threatening genetic disorders with a significant cumulative prevalence worldwide. Advances in early diagnosis and treatment have significantly increased life expectancy, underscoring the need for specialised adult care units and the establishment of structured transition programmes from paediatric to adult services. We hereby present a functional transition model for IEM patients and share our implementation experience. Methods: Initiated in 2012, the partnership between the paediatric Hospital Sant Joan de Déu (HSJD) and the adult-care centre at Hospital Clinic of Barcelona (HCB) culminated in 2019 with the transference of the first IEM patients under the structured A10! Programme. This model is structured around the transition units of paediatric and adult centres to guarantee communication and functional management. Regular monthly meetings at each centre and joint quarterly sessions allowed for protocol harmonisation and personalised care planning. Coordinated engagement of the multidisciplinary health care teams with patients and families smoothed the transfer process. Results: Between 2019 and 2024, 94 IEM patients were successfully transferred. Diagnoses included intermediary metabolism defects (71.23%), lipid metabolism and transport disorders (4.25%), heterocyclic compound metabolism (2.12%), complex molecules and organelle dysfunction (6.37%), cofactor and mineral metabolism (2.12%), signalling defects (5.31%), and unclassified cases (8.51% of rare disorders, maybe non-IEM). Transition formats included 21 in-person joint visits in HSJD, 37 remote transitions during the COVID-19 pandemic, and 36 streamlined transfers via standardised protocols. Sessions, trainings, and meetings allowed the exchange of patients’ needs and protocols. Conclusions: The successful transference of IEM patients requires structured programmes with interdisciplinary paediatric and adult teams, joining efforts with the patient, families, and caregivers. Communication between paediatric and adult transition units is essential to promote continuity of care and patient empowerment. While constantly updated, this model has proven effective, gaining positive evaluations from healthcare professionals and patients alike, representing a scalable framework for lifelong management of IEM in adult care settings.